BAN2401

Unassigned

New Medicines

Early Alzheimer's disease

Information

New molecular entity
Eisai
Eisai

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

Humanised immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively binds and clear protofibrils, large highly-toxic soluble aggregates of beta-amyloid that have been implicated in the development of Alzheimers Disease.
Alzheimers disease is the most common form of dementia, accounting for around 50% of cases. It is estimated to affect 496,000 people in the UK [1].
Early Alzheimer's disease
Intravenous infusion